Article citationsMore>>

Dalamaga, M., Archondakis, S., Sotiropoulos, G., Karmaniolas, K., Pelekanos, N., Papadavid, E. and Lekka, A. (2012) Could Serum Visfatin Be a Potential Biomarker for Postmenopausal Breast Cancer. Maturitas, 71, 301-308.
https://doi.org/10.1016/j.maturitas.2011.12.013

has been cited by the following article:

• TITLE: Serum Lipids and Lipokines as Prognostic/Diagnostic Biomarkers in Common Cancers

  AUTHORS: Nikolaos Dogkas, Maria Τrapali, Christine Fountzoula, Georgios Albert Karikas, Petros Karkalousos

  KEYWORDS: Cancer, Total Cholesterol, Triglycerides, HDL, LDL, Resistin, Visfatin

  JOURNAL NAME: Journal of Diabetes Mellitus, Vol.12 No.2, May 26, 2022

  ABSTRACT: Total cholesterol (CHOL) levels have been shown in many studies, to be higher in people with several types of cancer. Similar results are observed for both triglycerides (TG) and low-density cholesterol (LDL), as opposed to high-density cholesterol (HDL). Chemotherapy seems to reduce CHOL and LDL, leading to a reduction. Furthermore, the recurrence of high levels of CHOL, TG and LDL, as well as low levels of HDL, after receiving treatment, or when patients appear to have been cured, are signs of a possible recurrence of the disease. Lipoprotein α (Lpa), occurs at higher levels in patients than in healthy people, whereas lipokines resistin and bisfatin, “hormonal” products of adipose tissue exhibited high levels in cancer cases, compared to control groups.